Combined CD4 Th1 effect and lymphotactin transgene expression enhance CD8 Tc1 tumor localization and therapy (Q40435764)

20 September 2017

title

Combined CD4 Th1 effect and lymphotactin transgene expression enhance CD8 Tc1 tumor localization and therapy (English)

1 reference

20 September 2017

Huang H

1

1 reference

20 September 2017

Bi XG

2

1 reference

20 September 2017

Yuan JY

3

1 reference

20 September 2017

Xu SL

4

1 reference

20 September 2017

Guo XL

5

1 reference

20 September 2017

Xiang J

6

1 reference

20 September 2017

publication date

1 June 2005

1 reference

20 September 2017

1 reference

20 September 2017

volume

12

1 reference

20 September 2017

issue

12

1 reference

20 September 2017

page(s)

999-1010

1 reference

Treatment of Murine Gliomas by Adoptive Transfer ofex VivoActivated Tumor-Draining Lymph Node Cells

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302486

Generation of polarized antigen-specific CD8 effector populations: reciprocal action of interleukin (IL)-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302486

Type 1 and type 2: a fundamental dichotomy for all T-cell subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302486

Perforin and Fas killing by CD8 T cells limits their cytokine synthesis and proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302486

The expanding universe of T-cell subsets: Th1, Th2 and more.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302486

The role of CD4 tumor-infiltrating lymphocytes in human solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302486

Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302486

Help for cytotoxic-T-cell responses is mediated by CD40 signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302486

T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302486

A conditioned dendritic cell can be a temporal bridge between a CD4 T-helper and a T-killer cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302486

Tumor-specific CD4 T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302486

Lymphotactin: a cytokine that represents a new class of chemokine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302486

Neutrophils and B cells express XCR1 receptor and chemotactically respond to lymphotactin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302486

T cell receptor antagonist peptides induce positive selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302486

Regression of engineered tumor cells secreting cytokines is related to a shift in host cytokine profile from type 2 to type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302486

Lymphocyte-mediated cytotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302486

Synergistic effect of adoptive T-cell therapy and intratumoral interferon gamma-inducible protein-10 transgene expression in treatment of established tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302486

Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302486

Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302486

Specific T Helper Cell Requirement for Optimal Induction of Cytotoxic T Lymphocytes against Major Histocompatibility Complex Class II Negative Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302486

Th1 and Th2 cell clones to a poorly immunogenic tumor antigen initiate CD8 T cell-dependent tumor eradication in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302486

Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302486

Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302486

Cell-Associated Ovalbumin Is Cross-Presented Much More Efficiently than Soluble Ovalbumin In Vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302486

Treatment of subcutaneous tumor with adoptively transferred T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302486

7 January 2021

Type 1 and type 2 CD8 effector T cell subpopulations promote long-term tumor immunity and protection to progressively growing tumor

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302486

7 January 2021

The role of adoptively transferred CD8 T cells and host cells in the control of the growth of the EG7 thymoma: factors that determine the relative effectiveness and homing properties of Tc1 and Tc2 effectors

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302486

7 January 2021

Cutting edge: CD4 and CD8 T cells are intrinsically different in their proliferative responses

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302486

7 January 2021

A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302486

7 January 2021

Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302486

7 January 2021

Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302486

7 January 2021

Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302486

7 January 2021

Priming of naive T cells inside tumors leads to eradication of established tumors

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302486

7 January 2021

Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8( ) cytotoxic T-cell activation and antitumor immunity

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302486

7 January 2021

Enhanced HER-2/neu-specific antitumor immunity by cotransduction of mouse dendritic cells with two genes encoding HER-2/neu and alpha tumor necrosis factor

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302486

7 January 2021

Identifiers

DOI

10.1038/SJ.GT.3302486

1 reference

Dimensions Publication ID

20 September 2017

1007693060

0 references

1 reference